低正常与高正常氧合目标对危重患者器官功能障碍的影响:一项随机临床试验
该多中心随机临床试验在荷兰4个ICU纳入574例≥2项SIRS标准且预期停留>48小时的成人患者,比较低正常PaO2目标(8-12 kPa,n=205)与高正常目标(14-18 kPa,n=195)。机械通气时长、院内死亡率无显著差异;研究可能把握度不足以检测更小治疗效应。
要点
- 急性肾衰竭发生率低正常组10% vs 高正常组11%,急性心肌梗死2.9% vs 3.6%。
- 研究可能把握度有限,无法检测比预设更小的治疗效应;结果不支持常规采用低正常PaO2目标来减少器官功能障碍。
适用人群与场景
- 成人危重患者,入住ICU时符合≥2项SIRS标准,且预期停留时间>48小时。
- 研究在荷兰4个ICU进行,纳入时间为2015年2月至2018年10月。
- 排除标准原文未提及。
诊断标准与关键阈值
- SIRS标准:需符合≥2项SIRS criteria(具体各项条件原文未提及)。
- 低正常PaO2目标范围:8-12 kPa;高正常PaO2目标范围:14-18 kPa。
- 仅在临床有指征时使用吸入氧浓度>0.60。
处置流程与药物剂量
- 第一步:筛选成人ICU患者,确认符合≥2项SIRS标准且预期ICU停留>48小时。
- 第二步:随机分配至低正常PaO2目标(8-12 kPa)或高正常PaO2目标(14-18 kPa)。
- 第三步:按目标范围管理氧疗;仅当临床有指征时使用吸入氧浓度>0.60。
- 药物剂量、给药途径、频次或疗程原文未提及。
红旗征与不能漏的情况
- 急性肾衰竭(低正常组10% vs 高正常组11%)和急性心肌梗死(2.9% vs 3.6%)在两组均有发生,原文未给出针对这些情况的 specific 处理。
研究设计与关键结果
- 研究类型:多中心随机临床试验,荷兰4个ICU,纳入574例成人危重患者(低正常组n=205,高正常组n=195),400例(70%)在24小时内入组,中位年龄68岁,女性140例(35%),全部完成试验。
证据类型、等级与局限
- 证据类型:多中心随机临床试验(RCT)。
- 证据等级或推荐强度:原文未提及。
- 局限:研究可能把握度有限,无法检测比预设更小的治疗效应;原文未提及其他局限。
对床旁实践的改变
- 对于符合≥2项SIRS标准且预期ICU停留>48小时的成人危重患者,不常规采用低正常PaO2目标(8-12 kPa)来减少器官功能障碍,因与高正常目标(14-18 kPa)相比无显著获益。
- 低正常PaO2目标可能增加轻度低氧测量,需权衡低氧风险。
- 研究结果不适用于不符合≥2项SIRS标准或预期ICU停留≤48小时的患者。
- 研究把握度有限,不能排除较小治疗效应,临床决策需结合个体情况。
指南或共识出处
- 原文未提及指南或共识名称;试验注册号ClinicalTrials.gov NCT02321072。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Hyperoxemia may increase organ dysfunction in critically ill patients, but optimal oxygenation targets are unknown.
OBJECTIVE: To determine whether a low-normal Pao2 target compared with a high-normal target reduces organ dysfunction in critically ill patients with systemic inflammatory response syndrome (SIRS).
DESIGN, SETTING, AND PARTICIPANTS: Multicenter randomized clinical trial in 4 intensive care units in the Netherlands. Enrollment was from February 2015 to October 2018, with end of follow-up to January 2019, and included adult patients admitted with 2 or more SIRS criteria and expected stay of longer than 48 hours. A total of 9925 patients were screened for eligibility, of whom 574 fulfilled the enrollment criteria and were randomized.
INTERVENTIONS: Target Pao2 ranges were 8 to 12 kPa (low-normal, n = 205) and 14 to 18 kPa (high-normal, n = 195). An inspired oxygen fraction greater than 0.60 was applied only when clinically indicated.
MAIN OUTCOMES AND MEASURES: Primary end point was SOFARANK, a ranked outcome of nonrespiratory organ failure quantified by the nonrespiratory components of the Sequential Organ Failure Assessment (SOFA) score, summed over the first 14 study days. Participants were ranked from fastest organ failure improvement (lowest scores) to worsening organ failure or death (highest scores). Secondary end points were duration of mechanical ventilation, in-hospital mortality, and hypoxemic measurements.
RESULTS: Among the 574 patients who were randomized, 400 (70%) were enrolled within 24 hours (median age, 68 years; 140 women [35%]), all of whom completed the trial. The median Pao2 difference between the groups was -1.93 kPa (95% CI, -2.12 to -1.74; P < .001). The median SOFARANK score was -35 points in the low-normal Pao2 group vs -40 in the high-normal Pao2 group (median difference, 10 [95% CI, 0 to 21]; P = .06). There was no significant difference in median duration of mechanical ventilation (3.4 vs 3.1 days; median difference, -0.15 [95% CI, -0.88 to 0.47]; P = .59) and in-hospital mortality (32% vs 31%; odds ratio, 1.04 [95% CI, 0.67 to 1.63]; P = .91). Mild hypoxemic measurements occurred more often in the low-normal group (1.9% vs 1.2%; median difference, 0.73 [95% CI, 0.30 to 1.20]; P < .001). Acute kidney failure developed in 20 patients (10%) in the low-normal Pao2 group and 21 patients (11%) in the high-normal Pao2 group, and acute myocardial infarction in 6 patients (2.9%) in the low-normal Pao2 group and 7 patients (3.6%) in the high-normal Pao2 group.
CONCLUSIONS AND RELEVANCE: Among critically ill patients with 2 or more SIRS criteria, treatment with a low-normal Pao2 target compared with a high-normal Pao2 target did not result in a statistically significant reduction in organ dysfunction. However, the study may have had limited power to detect a smaller treatment effect than was hypothesized.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02321072.
参考来源
- Gelissen H, de Grooth HJ, Smulders Y, et al. Effect of Low-Normal vs High-Normal Oxygenation Targets on Organ Dysfunction in Critically Ill Patients: A Randomized Clinical Trial. JAMA. 2021. PMID: 34463696. doi:10.1001/jama.2021.13011
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。